mutLBSgeneDB |
Gene summary for TATDN3 |
![]() |
Basic gene Info. | Gene symbol | TATDN3 |
Gene name | TatD DNase domain containing 3 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 1q32.3 | |
Type of gene | protein-coding | |
RefGenes | NM_001042552.2, NM_001042553.2,NM_001146169.1,NM_001146170.1,NM_001146171.1, | |
Description | putative deoxyribonuclease TATDN3 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000203705 | ||
Vega : OTTHUMG00000036805 | ||
Protein | UniProt: Q17R31 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_TATDN3 | |
BioGPS: 128387 | ||
Pathway | NCI Pathway Interaction Database: TATDN3 | |
KEGG: TATDN3 | ||
REACTOME: TATDN3 | ||
Pathway Commons: TATDN3 | ||
Context | iHOP: TATDN3 | |
ligand binding site mutation search in PubMed: TATDN3 | ||
UCL Cancer Institute: TATDN3 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID |
Top |
Ligand binding site mutations for TATDN3 |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | H147 | V146A | HNSC | 1 | H170 | F172L | STAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for TATDN3 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | H170 | F172L | -1.3221978 | H147 | V146A | -1.2855924 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for TATDN3 |
![]() |
![]() |
Top |
Top |
Phenotype information for TATDN3 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for TATDN3 |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ZN | ZINC(2+) | 2y1h | A | H147 H170 | ZN | ZINC(2+) | 2y1h | B | H147 H170 | ZN | ZINC(2+) | 2y1h | A | H170 |
Top |
Conservation information for LBS of TATDN3 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |